Validated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy

被引:2
|
作者
Kaman, Kelsey [1 ,4 ]
Dhodapkar, Meera [2 ]
Shabanova, Veronika [2 ]
McCollum, Sarah [2 ]
Factor, Jeffrey [1 ,3 ]
Leeds, Stephanie [2 ]
机构
[1] Connecticut Asthma & Allergy Ctr, Hartford, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] New England Food Allergy Treatment Ctr, Hartford, CT USA
[4] Connecticut Asthma & Allergy Ctr, 836 Farmington Ave 207, Hartford, CT 06119 USA
关键词
QUALITY-OF-LIFE; FOOD ALLERGY; DISPARITIES; MANAGEMENT; SYMPTOMS; CHILDREN; STRESS; IMPACT;
D O I
10.1016/j.anai.2023.01.028
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Although efficacy, safety, and quality of life measures associated with peanut oral immunotherapy (OIT) have been studied, the relationship between peanut OIT and clinical anxiety has not yet been evaluated. The latter is important to help providers and families have an improved shared medical decision discussion around the benefits of initiating OIT.Objective: To investigate the relationship between undergoing OIT and anxiety in patients with peanut allergy.Methods: In this prospective cross-sectional cohort study, using validated and age-appropriate anxiety scales administered with electronic survey questionnaires, we used generalized linear regressions to compare anxiety between patients undergoing OIT and similar patients with peanut allergy but not on OIT (controls).Results: In the younger cohort (<7 years, n = 80), there was generally a low prevalence of diagnosable anxiety across patients on OIT and controls. In the older cohort (>7 years, n = 125), there was a higher prevalence of anx-iety but no clinically meaningful difference between anxiety scores of patients on OIT and controls. In the older cohort, patients with asthma were more likely to have higher mean anxiety scores (P = .04), as were female patients compared with male patients (P = .004). A subanalysis of separation anxiety scores in the older cohort revealed that younger age (7-12 years vs >12 years, P < .001), non-White race (P = .04), and eczema (P = .02) were found to be meaningful predictors of higher scores. A subanalysis of social anxiety on the older cohort pointed toward non-White race as a meaningful predictor of higher scores (P < .02).Conclusion: The clinical implications of these findings suggest that allergists should particularly consider screen-ing children with food allergy for anxiety and anxiety subtypes among patients who are non-White, female, or have asthma.& COPY; 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 50 条
  • [11] Oral immunotherapy for treatment of peanut allergy
    Dunlop, Joan H.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (06) : 1152 - 1155
  • [12] Peanut Oral Immunotherapy and Omalizumab Treatment for Peanut Allergy
    Henson, M.
    Edie, A.
    Steele, P.
    Kamilaris, J.
    Kulis, M.
    Thyagarajan, A.
    Vickery, B. P.
    Burks, A. W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB28 - AB28
  • [13] Comparison of sublingual immunotherapy and oral immunotherapy in peanut allergy
    Zhang W.
    Sindher S.B.
    Sampath V.
    Nadeau K.
    Allergo Journal International, 2018, 27 (6) : 153 - 161
  • [14] Safety of Peanut Oral Immunotherapy in Preschoolers at a Pediatric Academic Food Allergy Center
    Vickery, Brian
    Horton, Codi
    Leef, Chelsea
    Bai, Shasha
    Ezhuthachan, Idil
    Lee, Tricia
    Lee, Gerald
    Rathkopf, Melinda
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB119 - AB119
  • [15] Safety of a peanut oral immunotherapy protocol in children with peanut allergy
    Hofmann, Alison M.
    Scurlock, Amy M.
    Jones, Stacie M.
    Palmer, Kricia P.
    Lokhnygina, Yuliya
    Steele, Pamela H.
    Kamilaris, Janet
    Burks, A. Wesley
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (02) : 286 - 291
  • [16] Probiotics and oral immunotherapy for peanut allergy reply
    Tang, Mimi L. K.
    Hsiao, Kuang-Chih
    Ponsonby, Anne-Louise
    Donath, Susan
    Orsini, Francesca
    Axelrad, Christine
    Pitkin, Sigrid
    LANCET CHILD & ADOLESCENT HEALTH, 2017, 1 (03): : E1 - E2
  • [17] ORAL PEANUT IMMUNOTHERAPY (OPI) IN THE ALLERGY OFFICE
    Mansfield, L. E.
    Wasserman, R.
    Hutteman, H. R.
    Ruvalcaba, M.
    Galluci, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A121 - A121
  • [18] Peanut Allergy: oral Immunotherapy for Children and Adolescents
    Kempe, Sabrina
    ALLERGO JOURNAL, 2021, 30 (07) : 46 - 46
  • [19] Peanut allergy: Beyond the oral immunotherapy plateau
    Bruton, Kelly
    Spill, Paul
    Chu, Derek K.
    Waserman, Susan
    Jordana, Manel
    CLINICAL AND TRANSLATIONAL ALLERGY, 2021, 11 (06)
  • [20] Oral immunotherapy for peanut allergy: The con argument
    Fiocchi, Alessandro
    Artesani, Maria Cristina
    Fierro, Vincenzo
    Riccardi, Carla
    Dahdah, Lamia
    Mennini, Maurizio
    WORLD ALLERGY ORGANIZATION JOURNAL, 2020, 13 (08):